FDA Announces Public Workshop on Review of Clinical Safety Data in New Drug Applications

Summary

The Food and Drug Administration (FDA) is hosting a public workshop to gather input from the pharmaceutical industry, academia, and the public on the principles and methods used by the FDA in reviewing clinical safety data for new drug products, with the goal of developing a guidance document for reviewers.